Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02OZT
|
|||
| Former ID |
DIB012747
|
|||
| Drug Name |
DCR-MYC
|
|||
| Drug Type |
siRNA drug
|
|||
| Indication | Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 1/2 | [1] | |
| Company |
Dicerna pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | MYCBP messenger RNA (MYCBP mRNA) | Target Info | . | [2] |
| Panther Pathway | PDGF signaling pathway | |||
| Pathway Interaction Database | Notch signaling pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02314052) Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma. U.S. National Institutes of Health. | |||
| REF 2 | National Cancer Institute Drug Dictionary (drug id 759983). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.